http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106906186-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10034 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate | 2017-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106906186-B |
| titleOfInvention | A multi-epitope vaccine candidate strain for simultaneously preventing human adenovirus type 3-human adenovirus type 55-human adenovirus type 7 |
| abstract | The invention relates to the technical field of recombinant virus genetic engineering, in particular to a multi-epitope vaccine candidate strain for simultaneous prevention of human adenovirus type 3, human adenovirus type 55, and human adenovirus type 7, which can be expressed in human adenovirus type 3 hexon Human adenovirus type 55 neutralizing epitope 55R2 and human adenovirus type 7 neutralizing epitope 7R5 were inserted into the HVR2 region and HVR5 region of the human adenovirus type 7 respectively. Virus immune response, the vaccine candidate strain can be used to prepare a trivalent vaccine for preventing human type 3, type 7, and type 55 adenoviruses. |
| priorityDate | 2017-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.